Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

GSK receives EMA approval for new breast cancer treatment Tyverb

bs_subtitle

The European Medicines Agency (EMA) has granted an update to the marketing authorisation for Tyverb® (lapatinib) to be used in combination with Herceptin® (trastuzumab). This combination is indicated for adult patients with breast cancer whose tumours overexpress HER2 (ErbB2) with hormone receptor-negative (HR-) metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy. “We are proud to bring a new chemotherapy-free option to metastatic breast cancer patients. Through vertical dual blockade of the HER2 receptor, the combination of  lapatinib and trastuzumab achieves a clinically significant improvement in overall survival for patients with HER2-positive, HR-negative metastatic breast cancer,”

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy